The Claim
In adults with type 2 diabetes and chronic kidney disease, treatment with semaglutide reduces the urinary albumin-to-creatinine ratio (UACR) by approximately 30% compared to placebo after 104 weeks of treatment, regardless of baseline use of mineralocorticoid receptor antagonists.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with type 2 diabetes and kidney disease, a medication called semaglutide lowers a marker of kidney damage (urinary albumin-to-creatinine ratio) by about 30% after two years compared to a placebo, and this effect does not depend on whether they were already taking mineralocorticoid receptor antagonists.
See the scientific wording
In adults with type 2 diabetes and chronic kidney disease, semaglutide reduces urinary albumin-to-creatinine ratio (UACR) by approximately 30% compared to placebo at 104 weeks, with no statistically significant difference in effect between those using or not using mineralocorticoid receptor antagonists at baseline.
Semaglutide lowers blood pressure inside the kidney's filtering units, reduces swelling and damage to the cells that block protein leakage, and decreases inflammatory signals in the kidney tissue, which together stop albumin from escaping into the urine.
What the research says
1 studySemaglutide lowered a sign of kidney damage by about 30% in people with diabetes and kidney disease, whether or not they were already taking another kidney medicine — so the effect works either way.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.